

Freedom of Information Act 2000 - Request Reference FoI/22/441

Biologic Drugs used in Dermatology

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Abatacept	0
Adalimumab - Humira	10
Adalimumab Biosimilar	110
Apremilast	*
Bimekizumab	2
Brodalumab	7
Certolizumab	2
Dimethyl fumarate	*
Etanercept - Enbrel	0
Etanercept Biosimilar	7(Benepali)
Golimumab	0
Guselkumab	9
Infliximab - Remicade	0
Infliximab Biosimilar	12(Flixabi)
Ixekizumab	10
Risankizumab	6
Secukinumab	20
Tildrakizumab	1
Tofacitinib	6
Ustekinumab	41
Upadacitinib	1

*Please note: Cardiff and Vale University Health Board (the UHB) does not hold this data. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these medications are prescribed in the community.

2. How many patients were treated in the last 3 months by the Dermatology department for **Psoriatic Arthritis (PsA) ONLY** with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab

- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Ustekinumab

There are no Psoriatic Arthritis only patients on biologics in Dermatology